Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-
Vomiting
Rush University Medical CenterSmall moleculePhase 4 / ApprovedDormant
A
81/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 72/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Vomiting cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Zofran University of South Florida | Phase 4 | BBB |
DEXAMETHASONE Jun Zhu | Phase 4 | BB |
Tropisetron Jun Zhu | Phase 4 | BB |
Olanzapine Rush University Medical Center | Phase 3 | BB |
Capecitabine Wake Forest University Health Sciences | Phase 2 | B |
View all 19 →
Same molecule, other indications
Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →